# Astrocyte Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/astrocyte-pharmaceuticals

- Industry: Biotechnology
- Headquarters: US
- Website: www.astrocytepharma.com/
- Total disclosed funding: $23M
- Latest round: Series B (Sep 30, 2026)
- Investors on record: 14

## About

Founded in 2014 and based in Connecticut, US, Astrocyte Pharmaceuticals Inc. operates as a biotechnology company that focuses on developing program for treating brain injuries and disorders. William S. Korinek (CEO) and James D. Lechleiter are the co-founders of the company. In September 2026, Astrocyte Pharmaceuticals Inc. raised USD 9.5 million in series B funding led by DeepWork Capital, with participation from MintPharma Capital, Waterstar Capital, Dynagrow Capital, and Angel Star Ventures.

The company is developing treatments for medical needs in acute ischemic stroke, traumatic brain injury (TBI), concussion, and related conditions through research and development. The firm's lead candidate, AST-004, is a novel small molecule currently undergoing human Phase I clinical safety trials. This candidate is being tested in an intravenous injection formulation designed for use by emergency medical professionals in the treatment of acute ischemic stroke. In addition, this oral formulation is being explored for chronic administration to address neurodegenerative diseases such as Alzheimer's. Astrocyte Pharmaceuticals' pipeline includes several candidates at various stages of development, including AST-004 (Acute Ischemic Stroke), AST-004 (Severe-Moderate TBI), AST-004 (Concussion/Mild TBI), AST-004 (Alzheimer’s Disease), AST-008 (Pain/Migraine), and undisclosed candidates.

The company will use the September 2026 funding to improve its research platform, add personalization features, and hire across key teams.

## Funding rounds

- Series B, Sep 30, 2026, $9.5M — DeepWork Capital, WaterStar Capital, Angel Star Ventures, Dynagrow Capital, MintPharma Capital
- Series A, May 3, 2021, $6M — Boston Harbor Angels, Life Science Angels, Inc., Mass Medical Angels, Mid Atlantic Bio Angels, SideCar Angels, DeepWork Capital, Trend Investment Group, CR Ventures, DREAMERS Ventures, KYTO Technology & Life Science
- Series A, Nov 23, 2020, $7.5M — DeepWork Capital

## Investors

- DeepWork Capital (https://capitalatlas.ai/funds/deepwork-capital) — Series A, Series B
- Boston Harbor Angels — Series A
- Life Science Angels, Inc. — Series A
- Mass Medical Angels — Series A
- Mid Atlantic Bio Angels (https://capitalatlas.ai/funds/mid-atlantic-bio-angels) — Series A
- SideCar Angels (https://capitalatlas.ai/funds/sidecar-angels) — Series A
- Trend Investment Group (https://capitalatlas.ai/funds/trend-investment-group) — Series A
- CR Ventures (https://capitalatlas.ai/funds/cr-ventures) — Series A
- DREAMERS Ventures (https://capitalatlas.ai/funds/dreamers-ventures) — Series A
- KYTO Technology & Life Science (https://capitalatlas.ai/funds/kyto-technology-life-science) — Series A
- WaterStar Capital (https://capitalatlas.ai/funds/waterstar-capital) — Series B
- Angel Star Ventures (https://capitalatlas.ai/funds/angel-star-ventures) — Series B
- Dynagrow Capital — Series B
- MintPharma Capital — Series B